Navigation Links
Small molecule may disarm enemy of cancer-fighting p53
Date:12/7/2010

ORLANDO A pioneering clinical trial is testing the effectiveness in leukemia of a small molecule that shuts down MDM2, a protein that can disable the well-known tumor suppressor p53.

Michael Andreeff, M.D., Ph.D., professor of Medicine and chief of Molecular Hematology and Therapy in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, presented preliminary results of this ongoing Phase I study at the 52nd Annual Meeting of the American Society of Hematology. The clinical trial is under way at MD Anderson and five other sites in the United States and United Kingdom.

The first-in-class drug has shown clinical activity in some patients and been well-tolerated, Andreeff said.

Andreeff has been researching the interaction between MDM2 and p53 for five years. He says he believes this study may lead to an effective new way to fight some types of cancer with fewer side effects.

"P53 can be activated by chemotherapy or radiation, but both of these therapies carry risks of causing secondary tumors," he said. "If we can activate this tumor-suppressor with a method that is non-genotoxic and does not cause damage to a patient's DNA, we may be able to help avoid secondary tumors caused by other treatments."

Too much MDM2 degrades p53

Normally, p53 halts the division of defective cells and forces them to commit suicide or lose the ability to reproduce. However, the tumor suppressor is disabled in many types of cancer, often because of gene mutations or defective signaling.

While mutations of the TP53 gene are rare in cancers of the blood, the p53 protein may be degraded by other factors, including high levels of MDM2, which binds to p53 and orchestrates its degradation.

Previous research has suggested that p53 activation by disrupting the binding of MDM2 to p53 may be a novel strategy for cancer therapy. In preclinical studies, small-molecule MDM2 antagonists called Nutlins were found to be effective in solid tumors, leukemia and lymphoma.

The drug used in this study, RG7112, a novel small molecule being developed by Roche, is a member of the Nutlin family.

Clinical effects seen

Patients with relapsed or refractory acute or chronic leukemia were given RG7112 orally each day for 10 days, followed by 18 days of rest. Forty-seven patients, including 27 with acute myeloid leukemia (AML), have been treated to date.

There has been evidence of clinical activity, and one patient with AML has been leukemia-free for nine months. Reductions in lymph node and spleen size, as well as in circulating leukemia cells, were seen in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

"RG7112 has been well tolerated, and we've seen some effectiveness," Andreeff said. "So far it has done exactly what we thought it would. This gives us evidence it can be used in patients, is well-tolerated and can be given in dosages that can escalate to a point that shows a higher response rate."

Next steps

Enrollment in this study is ongoing and will be updated. Future single-agent and combination studies of RG7112 in leukemias are planned.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. Small assist device used in emergency case as twin, heart booster pumps for first time in US
2. Unexpectedly small effects of mutations in bacteria bring new perspectives
3. UCI non-small cell lung cancer study highlights advances in targeted drug therapy
4. Small particles show big promise in beating unpleasant odors
5. Small business success spotlighted by USDA at conference
6. American Chemical Society Webinar focuses on NSFs small business funding programs
7. Health Care Reform Helps Small Businesses Offer Coverage: Report
8. 16.6 million small business employees could benefit from ACA provisions starting this year
9. Babies Born Late May Face Small Cerebral Palsy Risk
10. Small Amounts of Dark Chocolate May Guard Against Heart Failure
11. Henry Ford Hospital study: Donor Risk Index does not impact outcomes on a small scale
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... ... 27, 2017 , ... GAFFEY Healthcare, a leading provider of ... to Vice President of Revenue Cycle Business Services and Suzanne Dusak to Vice ... executive officer (CEO). , Elrene has been with company since Oct 2014 and ...
(Date:7/27/2017)... Salt Lake City, Utah (PRWEB) , ... July 27, 2017 , ... Healthy eating isn’t ... of fruits and vegetables. At the same time, many Americans overeat refined grains and sugar. ... is that 36 percent of adults in the U.S. are obese. , As a culture, ...
(Date:7/27/2017)... ... July 27, 2017 , ... The Freedom ... form startup companies around 117 breakthrough inventions from 55 institutions, including the National ... National Institute of Biomedical Imaging and Bioengineering), the United States Army, and more ...
(Date:7/27/2017)... GREENWOOD VILLAGE, CO (PRWEB) , ... July 27, 2017 , ... ... According to the National Funeral Directors Association, this trend is expected to continue with ... this trend, there is a growing demand for new innovations that enable families to ...
(Date:7/26/2017)... ... July 26, 2017 , ... An inventor from Salisbury, N.C., knows ... yet seen an effective and dignified way to keep leeches in place during therapy," ... , This invention provides an effective way to keep a leech in place on ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... June 30, 2017, and updated its financial outlook for ... For the fiscal third quarter, Hill-Rom reported earnings of ... share in the prior-year period. These results reflect after-tax ... share primarily related to the non-cash write-down of assets ...
(Date:7/28/2017)... FLINT, Mich. , July 28, 2017 EnvoyHealth, ... (CMT) to pilot a program for CleverCap LITE, a ... CMT strives to deliver innovative health technology solutions ... adherence. CleverCap LITE ... The compact, high-tech bottle cover: ...
(Date:7/27/2017)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today ... 2017.  The Company reported second quarter net sales of ... year period, and an increase of 2.1% on a ... contribution from the LDR Holding Corporation acquisition, second quarter ... 2016, or 0.3% on a constant currency basis. ...
Breaking Medicine Technology: